Tag: Le

FDA Approves First CAR T-Cell for Adult ALL

The US Food and Drug Administration (FDA) has approved brexucabtagene autoleucel (Tecartus) for the treatment of adult patients (18 years and older) with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The therapy is the first chimeric antigen receptor (CAR) T-cell treatment approved for adults with ALL. This is a “meaningful advance,” because “roughly

Positive Topline Results of Novel Drug for PD Motor Fluctuations

Amneal Pharmaceuticals has announced positive topline results from the phase 3 RISE-PD trial evaluating a novel formulation of carbidopa/levodopa for patients with Parkinson’s disease (PD) who have motor fluctuations. “IPX-203 was developed with an innovative formulation that contains immediate-release and extended-release granules, and mucoadhesive polymers, to provide rapid absorption and maximize levodopa absorption,” the company

Long COVID, big bills: grim legacy of even short hospital stays

When COVID-19 patients are discharged from the hospital, most are far from being well—even if their hospital stay was fairly short. That’s among the initial findings of a study that followed Americans hospitalized for COVID-19 during the pandemic’s “third wave”—the fall of 2020 through early 2021. Researchers found that of 253 patients discharged from the